Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 62, Issue 1, 1996, Pages 100-102

  Rose, Peter G ^a   Blessing, John A ^b   Arseneau, James ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

EID: 0030200896     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0196     Document Type: Article

References (19)

1. 1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995, CA 45, 8-30 (1995).
2. 2. Park, R. C., and Thigpen, J. T. Chemotherapy in advanced and recurrent cervical cancer, Cancer 71, 1446-1450 (1993).
3. 3. Sutton, G. P., Blessing, J. A., Adcock, L., Webster, K. D., and DeEulis, T. Phase II study of ifosfamide and mesna in patients with previously treated carcinoma of the cervix: A Gynecologic Oncology Group study, Invest. New Drugs 7, 341-343 (1989).
4. 4. Ames, M. M. Hexamethylmelamine: Pharmacology and mechanism of action, Cancer Treat. Rev. 18, S3-S14 (1991).
5. 5. Gesher, A., D'Incalci, M, Fanelli, R., and Farina, P. N-Hydroxymethylpentamethylmelamine, a major in vitro metabolite of hexamethylmelamine, Life Sci. 26, 147-154 (1980).
6. 6. Miller, K. J., McGovern, R. M., and Ames, M. M. Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines, Cancer Chemother. Pharmacol. 15, 49-53 (1985).
7. 7. Foster, B. J., Harding, B. J., Leyland-Jones, B., and Hoth, D. Hexamethylmelamine: A critical review of an active drug, Cancer Treat. Rev. 13, 197-217 (1986).
8. 8. Stolinsky, D. C., Bogden, D. L., Solomon, J., and Bateman, J. R. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3,3-dimethyl-triazeno)imidazole-4-carboximide(NSC-45388) in the treatment of advanced cancer, Cancer 30, 654-659 (1972).
9. 9. Stolinsky, D. C., and Bateman, J. R. Further experience with hexamethylmelamine (NSC-13875) in the treatment of carcinoma of the cervix, Cancer Chemother. Rep. 57, 497-499 (1973).
10. 10. Freedman, R. S., Herson, J., Wharton, J. T., and Rutledge, F. N. Single-agent chemotherapy for recurrent carcinoma of the cervix, Cancer Clin. Trials 3, 345-350 (1980).
11. 11. Omura, G. A., Greco, F. A., and Birch, R. Hexamethylmelamine in mustard resistant ovarian adenocarcinoma, Cancer Treat. Rep. 65, 530-531 (1981).
12. 12. Johnson, B. L., Fisher, R. I., Bender, R. A., DeVita, V. T., Chabner, B. A., and Young, R. C. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma, Cancer 42, 2157-2161 (1978).
13. 13. Rosen, G. F., Lurain, J. R., and Newton, M. Hexamethylmelamine in ovarian cancer after failure of cisplatin based multiple agent chemotherapy, Gynecol. Oncol. 27, 173-179 (1987).
14. 14. Moore, D. H., Fowler, W. C., Jones, C. S., and Crumpler, L. S. Hexamethylmelamine chemotherapy for persistent or recurrent ovarian cancer, Am. J. Obstet. Gynecol. 165, 573-576 (1991).
15. 15. Vergote, I., Himmelmann, A., Frakendal, B., Scheistroen, M., Vlachos, K., and Trope, C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer, Gynecol. Oncol. 47, 282-286 (1992).
16. 16. Fields, A. L., Schink, J. C., Miller, D. S., Rademaker, A. W., and Lurain, J. R. Oral hexamethylmelamine: An effective salvage therapy for recurrent ovarian cancer, Int. J. Obstet. Gynecol. (Suppl.) 36, 515 (1991).
17. 17. Schink, J. C., Harris, L. S., Grosen, E. R., and Balley, W. H. Altretamine (Hexalen) an effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum resistant ovarian cancer, Proc. Am. Soc. Clin. Oncol. 14, 275 (1995).
18. 18. Seski, J. C., Edwards, C. L., Copeland, L. J., and Gershenson, D. M. Hexamethyl-melamine chemotherapy for disseminated endometrial cancer, Obstet. Gynecol. 58, 361-363 (1981).
19. 19. Thigpen, J. T., Blessing, J. A., Ball, H., Hanjam, P., Manetta, A., and Homesley, H. Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group, Gynecol. Oncol. 31, 435-438 (1988).